Seeking Alpha

Citigroup says it's learned that Gilead's (GILD -1.7%) Phase 3 Neutrino study in Hepatitis C...

Citigroup says it's learned that Gilead's (GILD -1.7%) Phase 3 Neutrino study in Hepatitis C patients was fully enrolled in July after only one month of recruitment, which points to tremendous potential demand for the company's Hepatitis C treatment GS-7977. The firm reiterates a Buy with a $65 price target.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs